Serum Growth Factors in Schizophrenia Patients

Some hypotheses include schizophrenia as a neurodevelopmental disorder, which indicates a special role in growth factors and neuroglia in the development of schizophrenia symptoms. Growth factors are cytokine molecules that play an important role in the regulation of tissue nucleation, cell development, survival, and migration of all tissues in organisms, including the brain and nervous system. The aim of the study was to determine the serum concentration of six growth factors (EGF, VEGF, FGF-2, TGF-α, PDGF-AA, PDGF-AB/BB) in schizophrenia patients and to identify the correlations with clinical characteristics. After signing an informed consent form, 236 schizophrenia patients (F20 according to the ICD-10) and 102 healthy people were recruited in the study. In patients with schizophrenia, we observed a significant elevation in the TGF-α and PDGF-AA serum levels. The duration of schizophrenia was significantly positively correlated with the FGF-2 level. The PANSS total score had a positive correlation with the FGF-2 level and a negative correlation with the TGF-α level. Our results and literature indicate the involvement of growth factors in the mechanisms of development of schizophrenia. Combined biomarker screening seems to be necessary to improve diagnosis and clinical follow-up of patients with severe mental illnesses.

[1]  V. Buneva,et al.  Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review , 2023, International journal of molecular sciences.

[2]  N. Bokhan,et al.  Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia , 2022, Life.

[3]  V. Kaleda,et al.  Thermal Balance of the Brain and Markers of Inflammatory Response in Patients with Schizophrenia , 2022, Bulletin of Experimental Biology and Medicine.

[4]  A. Loonen,et al.  Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex. , 2022, Acta neuropsychiatrica.

[5]  N. Bokhan,et al.  Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms , 2021, Life.

[6]  D. Ribatti,et al.  Involvement of vascular endothelial growth factor in schizophrenia , 2021, Neuroscience Letters.

[7]  N. Bokhan,et al.  Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics , 2021, Pharmaceuticals.

[8]  Z. Teng,et al.  Peripheral Blood Leukocyte RNA-Seq Identifies a Set of Genes Related to Abnormal Psychomotor Behavior Characteristics in Patients with Schizophrenia , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[9]  P. Buckley.  Neuroinflammation and Schizophrenia , 2019, Current Psychiatry Reports.

[10]  A. Teixeira,et al.  Inflammation in psychiatric disorders: what comes first? , 2019, Annals of the New York Academy of Sciences.

[11]  N. Müller.  Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations , 2018, Schizophrenia bulletin.

[12]  A. Lubeiro,et al.  Vascular endothelial growth factor in patients with schizophrenia: A systematic review and meta-analysis , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  P. Romero-Sanchiz,et al.  Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis , 2017, PeerJ.

[14]  A. Loonen,et al.  Circuits regulating pleasure and happiness: evolution and role in mental disorders * , 2017, Acta Neuropsychiatrica.

[15]  Ó. González-Pérez,et al.  Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. , 2016, Cytokine & growth factor reviews.

[16]  A. Vita,et al.  Schizophrenia , 2016, The Lancet.

[17]  B. Ham,et al.  Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment , 2015, Psychiatry Research.

[18]  D. D. De Silva,et al.  Elevated Platelet-Derived Growth Factor AB/BB is Associated with a Lower Risk of Recurrent Vascular Events in Stroke Patients , 2015, International journal of stroke : official journal of the International Stroke Society.

[19]  H. Nawa,et al.  Neuropathologic Implication of Peripheral Neuregulin-1 and EGF Signals in Dopaminergic Dysfunction and Behavioral Deficits Relevant to Schizophrenia: Their Target Cells and Time Window , 2014, BioMed research international.

[20]  V. Baekelandt,et al.  Neurogenesis as a new target for the development of antidepressant drugs. , 2014, Current pharmaceutical design.

[21]  A. Nambu,et al.  Exposure to the cytokine EGF leads to abnormal hyperactivity of pallidal GABA neurons: implications for schizophrenia and its modeling , 2013, Journal of neurochemistry.

[22]  S. R. Azua,et al.  Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  B. Bogerts,et al.  Concerning HB‐EGF Brain Levels in Schizophrenia: Cellular Distribution of Putative Sheddases May Matter , 2013, CNS neuroscience & therapeutics.

[24]  Stanley J. Watson,et al.  The Fibroblast Growth Factor Family: Neuromodulation of Affective Behavior , 2012, Neuron.

[25]  H. Hara,et al.  Essential Roles of Heparin‐Binding Epidermal Growth Factor‐Like Growth Factor in the Brain , 2012, CNS neuroscience & therapeutics.

[26]  Kerang Zhang,et al.  A study of the functional significance of epidermal growth factor in major depressive disorder , 2012, Psychiatric genetics.

[27]  M. Harirchian,et al.  Serum and CSF PDGF‐AA and FGF‐2 in relapsing‐remitting multiple sclerosis: a case–control study , 2012, European journal of neurology.

[28]  François Guillemot,et al.  From Cradle to Grave: The Multiple Roles of Fibroblast Growth Factors in Neural Development , 2011, Neuron.

[29]  T. Ono,et al.  Cognitive and Socio-Emotional Deficits in Platelet-Derived Growth Factor Receptor-β Gene Knockout Mice , 2011, PloS one.

[30]  Edward T. Bullmore,et al.  Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections , 2010, PloS one.

[31]  N. Andreasen,et al.  Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs , 2010, Biological Psychiatry.

[32]  A. Pillai,et al.  Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects , 2009, Schizophrenia Research.

[33]  S. Newton,et al.  Erythropoietin Induction by Electroconvulsive Seizure, Gene Regulation, and Antidepressant-Like Behavioral Effects , 2009, Biological Psychiatry.

[34]  G. Kirov,et al.  IGF1, growth pathway polymorphisms and schizophrenia: A pooling study , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[35]  Ole Isacson,et al.  Intrastriatal Transforming Growth Factor α Delivery to a Model of Parkinson's Disease Induces Proliferation and Migration of Endogenous Adult Neural Progenitor Cells without Differentiation into Dopaminergic Neurons , 2004, The Journal of Neuroscience.

[36]  P. Carmeliet,et al.  VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  R. Donnelly,et al.  Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[38]  F. Vaccarino,et al.  Fibroblast Growth Factor 2 Is Required for Maintaining the Neural Stem Cell Pool in the Mouse Brain Subventricular Zone , 2004, Developmental Neuroscience.

[39]  C. Betsholtz.  Biology of platelet-derived growth factors in development. , 2003, Birth defects research. Part C, Embryo today : reviews.

[40]  K. Hashimoto,et al.  Increased levels of serum basic fibroblast growth factor in schizophrenia , 2003, Psychiatry Research.

[41]  K. Jin,et al.  VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. , 2003, The Journal of clinical investigation.

[42]  K. Jin,et al.  Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Xin-Fu Zhou,et al.  Roles of transforming growth factor-α and related molecules in the nervous system , 1999, Molecular Neurobiology.

[44]  H. Antoniades.  PDGF: a multifunctional growth factor. , 1991, Bailliere's clinical endocrinology and metabolism.

[45]  A. Kakita,et al.  Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients , 2002, Molecular Psychiatry.

[46]  B. Marchetti.  The LHRH-astroglial network of signals as a model to study neuroimmune interactions: assessment of messenger systems and transduction mechanisms at cellular and molecular levels. , 1996, Neuroimmunomodulation.

[47]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.